OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a research report sent to investors on Sunday. The firm issued a sell rating on the medical research company’s stock.

OpGen Price Performance

Shares of OPGN opened at $1.90 on Friday. The company’s 50-day simple moving average is $2.28 and its 200-day simple moving average is $3.62. OpGen has a 1 year low of $1.75 and a 1 year high of $38.40.

OpGen (NASDAQ:OPGN) last released its earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 1,140.36%. The company had revenue of $0.03 million for the quarter.

Hedge Funds Weigh In On OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp bought a new position in shares of OpGen, Inc. (NASDAQ:OPGN) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 2.68% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.